Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period

Beitrag bei einer Tagung


Details zur Publikation

Autorinnen und Autoren: Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Oberg K, Warner RRP, Kunz PL, Kunz PL, Grande E, Valle JW, Dillon JS, Lapuerta P, Banks P, Jackson S, Pavel ME
Jahr der Veröffentlichung: 2018
Band: 47
Heftnummer: 3
Seitenbereich: 341-342
ISSN: 0885-3177


FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Pavel, Marianne Ellen
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie


Einrichtungen weiterer Autorinnen und Autoren

Dana–Farber Cancer Institute
Hospital Universitario Ramón y Cajal
Icahn School of Medicine at Mount Sinai
Lexicon Pharmaceuticals, Inc.
Royal Free Hospital
Stanford University
UCSF Helen Diller Family Comprehensive Cancer Center
University of Iowa
University of Kentucky
University of Manchester
Uppsala University
Zentralklinikum Bad Berka


Zitierweisen

APA:
Hoersch, D., Kulke, M.H., Caplin, M.E., Anthony, L.B., Bergsland, E., Oberg, K.,... Pavel, M.E. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period. (pp. 341-342).

MLA:
Hoersch, Dieter, et al. "Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period." 2018. 341-342.

BibTeX: 

Zuletzt aktualisiert 2019-25-01 um 07:38